换一批
换一批The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
第一作者：
Robert,Roskoski
第一单位：
Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC, 28742-8814, United States. Electronic address: rrj@brimr.org.
作者：
关键词
Catalytic spineCrenolanib: (PubMED CID: 49803313)FF10101: (PubMED CID: 90052320)Gilteritinib: (PubMED CID: 49803313)Hydrophobic interactionsImatinib: (PubMED CID: 5291)K/E/D/DLestaurtinib: (PubMED CID: 126565)Midostaurin: (PubMED CID: 9829523)Ponatinib: (PubMed CID: 24826799)Protein kinase inhibitor classificationProtein kinase structureQuizartinib: (PubMed CID: 24889392)Regulatory spineSorafenib: (PubMed CID: 216239)Sunitinib: (PubMed CID: 5329102)
主题词
投药, 口服(Administration, Oral);动物(Animals);抗肿瘤药(Antineoplastic Agents);人类(Humans);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);膜蛋白质类(Membrane Proteins);蛋白激酶抑制剂(Protein Kinase Inhibitors);fms样酪氨酸激酶3(fms-Like Tyrosine Kinase 3)
DOI
10.1016/j.phrs.2020.104725
PMID
32109580
发布时间
2021-03-29
- 浏览2
Pharmacological research
104725页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
